Basel, Switzerland and San Diego, CA – December 08, 2005 – Roche and Ambrx Inc. today announced a collaboration in which Ambrx will use its proprietary technology to develop next generation proteins and peptides. These new compounds could offer efficacy or safety advantages over currently marketed products. Roche and Ambrx will initial… Read More

San Diego, CA – September 20, 2005 – Ambrx, Inc., announced today the appointment of Martin A Mattingly, Pharm.D. as President and Chief Executive Officer, effective immediately. Dr. Mattingly will also join the company's board of directors. "Ambrx has made remarkable progress since… Read More

Washington, DC – June 21, 2005 – FierceBiotech today revealed its “Fierce 15” list of the top emerging biotech and pharmaceutical companies of 2005. This year's winners include cutting-edge businesses from across the globe whose innovative technologies are redefining the biotech industry. Some of the winning innovat… Read More

Copenhagen, Denmark – June 03, 2005 – CMC Biopharmaceuticals A/S, a Copenhagen based contract manufacturing organization, and Ambrx, Inc. a drug development company based in San Diego, CA announced today that they have entered into a development and manufacturing agreement for the cGMP production of a PEGylated recombin… Read More

SAN DIEGO, CA – April 13, 2005 – Ambrx, Inc., today announced the appointment of August M. Watanabe, M.D. to its Board of Directors. Dr. Watanabe was formerly a senior executive at Eli Lilly & Company, where he occupied the positions of Executive Vice President of Science and Technology, President of Lilly Resea… Read More

SAN DIEGO, CA – April 08, 2005 – Ambrx, Inc., today announced the completion of a $23.4 million preferred stock financing. The funds will be used to advance Ambrx's lead product candidate, a human growth hormone with enhanced pharmacologic performance, into clinical development and to exploit the company%2… Read More

San Diego, CA – April 06, 2005 – Ambrx, Inc., announced today the appointment of Bruce Kimmel, Ph.D. as Vice President, Therapeutic Applications. Dr. Kimmel brings great scientific strengths and therapeutic protein experience to a strategic leadership role at Ambrx, where he will advance application of the company… Read More